Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
- 17 April 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 35 (8), 1431-1438
- https://doi.org/10.1007/s00259-008-0769-2
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumoursNuclear Medicine Communications, 2007
- Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOCCancer Biotherapy & Radiopharmaceuticals, 2007
- Tumour biology and histopathology of neuroendocrine tumoursBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- Differential Expression of the Human Somatostatin Receptor Subtypes sst1 to sst5 in Various Adrenal Tumors and Normal Adrenal GlandHormone and Metabolic Research, 2005
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursGut, 2005
- Epidemiology of Neuroendocrine TumoursNeuroendocrinology, 2004
- Incidence and management of malignant digestive endocrine tumours in a well defined French populationGut, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Expression of Somatostatin Receptor and Effects of Somatostatin Analog on Pancreatic Endocrine TumorsSurgery Today, 2002
- Fully automated synthesis module for the high yield one-pot preparation of 6-[]fluoro-l-DOPAApplied Radiation and Isotopes, 1999